Darzalex ®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone approved for reimbursement in Ireland for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that Darzalex ®(daratumumab) in combination with lenalidomide and dexamethasone (DRd) has been reimbursed in Ireland for the treatment…
